QIAGEN N.V. (QGEN) stock
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$49.75−0.06 (-0.12%)
Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%
Qiagen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was $659.60M, up 119.2% from the year before. Over ten years it grew 5.9% a year on average. The highest annual figure on record is $845.02M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $659.60M | +119.2% |
| FY2024 | Dec 31, 2024 | $300.98M | -51.1% |
| FY2023 | Dec 31, 2023 | $615.27M | -16.8% |
| FY2022 | Dec 31, 2022 | $739.86M | -12.4% |
| FY2021 | Dec 31, 2021 | $845.02M | +42.9% |
| FY2020 | Dec 31, 2020 | $591.45M | +188.1% |
| FY2019 | Dec 31, 2019 | $205.32M | -56.6% |
| FY2018 | Dec 31, 2018 | $473.02M | +27.9% |
| FY2017 | Dec 31, 2017 | $369.87M | +18.6% |
| FY2016 | Dec 31, 2016 | $311.88M | -15.9% |
| FY2015 | Dec 31, 2015 | $370.97M | +2.3% |
| FY2014 | Dec 31, 2014 | $362.48M | +38.0% |
| FY2013 | Dec 31, 2013 | $262.69M | -28.6% |
| FY2012 | Dec 31, 2012 | $367.71M | +37.7% |
| FY2011 | Dec 31, 2011 | $266.97M | -19.4% |
| FY2010 | Dec 31, 2010 | $331.32M | +44.8% |
| FY2009 | Dec 31, 2009 | $228.78M | +21.5% |
| FY2008 | Dec 31, 2008 | $188.28M | – |
See a number that looks wrong?